Sulfur hexafluoride

Identification

Name
Sulfur hexafluoride
Accession Number
DB11104
Type
Small Molecule
Groups
Approved
Description

Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients

Structure
Thumb
Synonyms
  • hexafluoridosulfur
  • Sulfur fluoride
  • sulfur(6+) fluoride
  • sulfur(VI) fluoride
  • Sulphur hexafluoride
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SonovueInjection, powder, for solution8 μl/mlIntravenousBracco International B.V.2001-03-26Not applicableEu
SonovuePowder, for suspension8 mclIntravenousBracco Imaging S.P.A.2016-09-22Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
LumaSonSulfur hexafluoride (60.7 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg)KitBracco Diagnostics, Inc2015-01-15Not applicableUs
Categories
UNII
WS7LR3I1D6
CAS number
2551-62-4
Weight
Average: 146.05
Monoisotopic: 145.962490152
Chemical Formula
F6S
InChI Key
SFZCNBIFKDRMGX-UHFFFAOYSA-N
InChI
InChI=1S/F6S/c1-7(2,3,4,5)6
IUPAC Name
hexafluoro-λ⁶-sulfane
SMILES
FS(F)(F)(F)(F)F

Pharmacology

Indication

Echocardiography: Sulfur hexafluoride is indicated for use in adult patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricularendocardial border. Ultrasonography of the Liver: Sulfur hexafluoride is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions.

Pharmacodynamics

Sulfur hexafluoride provides useful echocardiographic signal intensity for two minutes after the injection. Sulfur hexafluoride microspheres are destroyed and contrast enhancement decreases as the mechanical index increases (values of 0.8 or less are recommended). For ultrasonography of the liver, Sulfur hexafluoride provides dynamic patterns of differential signal intensity enhancement between focal liver lesions and liver parenchyma during the arterial, portal venous, and late phase of signal intensity enhancement of the microvasculature.

Mechanism of action

Within the blood, the acoustic impedance of Lumason microspheres is lower than that of the surrounding non-aqueous tissue. Therefore, an ultrasound beam is reflected from the interface between the microspheres and the surrounding tissue. The reflected ultrasound signal provides a visual image that shows a contrast between the blood and the surrounding tissues.

Absorption

The pharmacokinetic of the SF6 gas component of Lumason was evaluated in 12 healthy adult subjects (7 men and 5 women). After intravenous bolus injections of 0.03 mL/kg and 0.3 mL/kg of Lumason, corresponding to approximately 1 and 10 times the recommended doses, concentrations of SF6 in blood peaked within 1 to 2 minutes for both doses.

Volume of distribution

In a study of healthy subjects, the mean values for the apparent steady-state volume of distribution of SF6 were 341 L and 710 L for Lumason doses of 0.03 mL/kg and 0.3 mL/kg, respectively. Preferential distribution to the lung is likely responsible for these values.

Protein binding
Not Available
Metabolism

SF6 undergoes little or no biotransformation; 88% of an administered dose is recovered unchanged in expired air.

Route of elimination

The SF6 component of Lumason is eliminated via the lungs.

Half life

The terminal half-life of SF6 in blood was approximately 10 minutes for the 0.3 mL/kg dose. (At the 0.03 mL/kg dose, terminal half-life could not be estimated.)

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. FDA label [Link]
External Links
KEGG Drug
D05962
PubChem Compound
17358
PubChem Substance
347827897
ChemSpider
16425
ChEBI
30496
ChEMBL
CHEMBL1796998
Wikipedia
Sulfur_hexafluoride
ATC Codes
V08DA05 — Sulfur hexafluoride
AHFS Codes
  • 36:89.00* — Other Diagnostics

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingDevice FeasibilityStroke, Acute1
0Not Yet RecruitingDiagnosticAsbestosis / Asthma Bronchial / Bronchiectasis / Chronic Obstructive Pulmonary Disease (COPD) / Cold Virus / Cystic Fibrosis (CF) / Emphysema / Interstitial Lung Disease (ILD) / Lung Cancers / Lung Infection / Lung Resection / Lung Transplant / Mesothelioma / Obstructive Sleep Apnea (OSA) / Pulmonary Dysplasia / Pulmonary Embolism (PE) / Pulmonary Fibrosis / Pulmonary Hypertension (PH) / Seasonal Allergies1
0RecruitingDiagnosticDevelopmental Dysplasia of the Hip (DDH)1
0RecruitingDiagnosticDiseases of Liver / Hepatocellular,Carcinoma1
1Not Yet RecruitingDiagnosticAppendicitis Acute1
1RecruitingBasic ScienceAtherosclerosis of Artery / Fibromuscular Dysplasia of Arteries / Segmental Arterial Mediolysis / Spontaneous Coronary Artery Dissection1
1RecruitingDiagnosticTransplantation, Kidney1
1, 2Not Yet RecruitingTreatmentNeoplasms, Breast / Neoplasms, Colorectal1
1, 2RecruitingDiagnosticAbdominal Injuries1
1, 2WithdrawnDiagnosticCoronary Artery Disease1
2CompletedNot AvailablePulmonary Hypertension (PH)1
2CompletedDiagnosticUrinary Tract Infections (UTIs) / Vesicoureteral Reflux1
2Not Yet RecruitingDiagnosticAppendicitis Acute1
2RecruitingBasic ScienceCarotid Artery Plaque1
3CompletedDiagnosticAtherosclerosis / Carotid Artery Plaque / Stroke, Ischemic1
3CompletedDiagnosticCoronary Artery Disease2
3CompletedDiagnosticLiver Lesions1
3CompletedDiagnosticNeoplasms, Hepatic1
3CompletedTreatmentRetinal Detachment / Vitreoretinopathy, Proliferative1
3Not Yet RecruitingDiagnosticBowel Ischemic / Necrotizing Enterocolitis of Newborn1
3RecruitingDiagnosticBrain Ischemia Hypoxia / Hypoxic-Ischaemic Encephalopathy1
3RecruitingTreatmentEarly Primary Breast Cancer1
3TerminatedDiagnosticCongenital Heart Disease (CHD)1
3TerminatedTreatmentStroke, Ischemic1
4Enrolling by InvitationDiagnosticCrohn's Disease (CD)1
4Not Yet RecruitingDiagnosticVesico-Ureteral Reflux1
4RecruitingDiagnosticLiver Biopsy1
4RecruitingDiagnosticTrauma Abdomen1
4WithdrawnDiagnosticNeonatal Post-Hemorrhagic Hydrocephalus1
Not AvailableCompletedDiagnosticAdenocarcinoma of the Pancreas1
Not AvailableCompletedDiagnosticPlacenta Accreta1
Not AvailableCompletedDiagnosticTumors, Breast1
Not AvailableNot Yet RecruitingDiagnosticHepatocellular,Carcinoma1
Not AvailableRecruitingNot AvailableCrohn's Disease (CD)1
Not AvailableRecruitingDiagnosticProstate Cancer / Prostatic Neoplasms1
Not AvailableTerminatedDiagnosticProstate Cancer1
Not AvailableUnknown StatusDiagnosticMalignant Neoplasm, Overlapping Lesion of Breast1
Not AvailableUnknown StatusTreatmentHydrops in Keratoconus1
Not AvailableUnknown StatusTreatmentRhegmatogenous Retinal Detachments1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit
Injection, powder, for solutionIntravenous8 μl/ml
Powder, for suspensionIntravenous8 mcl
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5686060No1997-11-112017-11-11Us

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP2.28ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity18.44 m3·mol-1ChemAxon
Polarizability7.11 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as other non-metal halides. These are inorganic compounds containing 'other non-metals' and halogen.
Kingdom
Inorganic compounds
Super Class
Homogeneous non-metal compounds
Class
Other non-metal halides
Sub Class
Not Available
Direct Parent
Other non-metal halides
Alternative Parents
Not Available
Substituents
Other non-metal halide
Molecular Framework
Not Available
External Descriptors
sulfur coordination entity (CHEBI:30496)

Drug created on December 03, 2015 09:51 / Updated on October 16, 2018 08:43